Status: Recruiting
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Participants needed: 75
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SURGE TherapeuticsUpdated: May 27, 2026Locations: 20
Eligibility criteria
Are aged 18 years or older; [+9]
Have a history of CIS or MIBC; [+4]